First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies
The...

Related Keywords

Hamburg ,Germany ,United States ,Eppendorf ,Nordrhein Westfalen ,Peter Maag ,Christoph Heesen ,Department Of Stem Cell Transplantation ,National Institutes Of Health ,University Medical Center Hamburg ,Kyverna Therapeutics Inc ,Kyverna Therapeutics ,University Medical Center Hamburg Eppendorf ,Stem Cell Transplantation ,Northern European ,National Institutes ,Media Contact ,Nature Medicine ,Markets ,